Initiation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with reduced emergency department visits, fewer hospitalizations, and lower escalation to additional preventive therapies compared to topiramate in adults with chronic migraine, according to an observational real-world cohort study. This study highlights the potential benefits of GLP-1 RAs in managing chronic migraine symptoms, but further research is needed to establish causation.
Background
Chronic migraine is a debilitating condition characterized by frequent headache days, significantly impacting patients' quality of life. Traditional preventive therapies include medications like topiramate and beta-blockers, but many patients experience inadequate relief or adverse effects. The exploration of GLP-1 RAs, originally developed for diabetes management, offers a novel approach to potentially stabilize migraine-related disease burden.
Data Highlights
Outcome
GLP-1 RAs
Topiramate
Risk Ratio
Emergency Department Visits
24%
26%
0.90
Hospitalizations
Lower
Higher
0.86
Nerve Block Procedures
Lower
Higher
0.87
Triptan Prescriptions
Lower
Higher
0.87
Additional Preventive Medications
Lower
Higher
Varied (e.g., Valproate 0.52, CGRP mAbs 0.58)
Key Findings
GLP-1 RA initiation resulted in a 10% lower rate of emergency department visits compared to topiramate.
Patients on GLP-1 RAs had a 14% lower hospitalization rate than those on topiramate.
Lower rates of nerve block procedures (risk ratio 0.87) were observed in the GLP-1 RA group.
Triptan prescriptions were also reduced in patients initiating GLP-1 RAs (risk ratio 0.87).
Patients starting GLP-1 RAs were less likely to begin additional preventive therapies, including valproate (risk ratio 0.52) and CGRP monoclonal antibodies (risk ratio 0.58).
Clinical Implications
The findings suggest that GLP-1 RAs may offer a beneficial alternative for chronic migraine management, potentially reducing the need for emergency care and additional medications. However, clinicians should note the lack of randomized controlled trials assessing the preventive efficacy of GLP-1 RAs and consider their role in treatment plans, particularly for patients with comorbid conditions such as obesity or diabetes.
Conclusion
This study indicates that GLP-1 RAs may provide significant advantages in managing chronic migraine, warranting further investigation into their preventive efficacy and the mechanisms underlying these associations.
Older patients with documented cognitive impairment also experienced greater postoperative functional decline following elective total knee arthroplasty
With an aging population, spine disorders are becoming increasingly common. Age-related spinal degeneration is nearly universal, but not all patients experience symptoms—and not all degeneration progresses the same way.
